DDrare: Database of Drug Development for Rare Diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
265	脂肪萎縮症	1

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00426296 (ClinicalTrials.gov)	August 2006	23/1/2007	SHARE: Simple HAART With Abacavir, Reyataz, and Epivir	An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of a Fixed-Dose Combination of Abacavir 600 mg/Lamivudine 300 mg Once-Daily in Combination With Atazanavir 300 mg + Ritonavir 100 mg Once-Daily in Antiretroviral-Naïve HIV-1 Infected Subjects With Continuing Evaluation of Abacavir/Lamivudine Plus Atazanavir 400 mg for Maintenance Over an Additional 48 Weeks	HIV Infections;Lipodystrophy	Drug: atazanavir (Reyataz);Drug: ritonavir (Norvir)	Clinical Alliance for Research & Education - Infectious Diseases, LLC.	GlaxoSmithKline	Recruiting	18 Years	N/A	Both		Phase 4	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT00426296
(ClinicalTrials.gov)

August 2006

23/1/2007

SHARE: Simple HAART With Abacavir, Reyataz, and Epivir

An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of a Fixed-Dose Combination of Abacavir 600 mg/Lamivudine 300 mg Once-Daily in Combination With Atazanavir 300 mg + Ritonavir 100 mg Once-Daily in Antiretroviral-Naïve HIV-1 Infected Subjects With Continuing Evaluation of Abacavir/Lamivudine Plus Atazanavir 400 mg for Maintenance Over an Additional 48 Weeks

HIV Infections;Lipodystrophy

Drug: atazanavir (Reyataz);Drug: ritonavir (Norvir)

Clinical Alliance for Research & Education - Infectious Diseases, LLC.

GlaxoSmithKline

Recruiting

18 Years

N/A

Both

Phase 4

United States